Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Table 9 Test 2: Adverse Event Rates

	Treatment-Emergent Diabetes				Treatment-Emergent Hyperlipidemia
	New Event Rate* (Base Case Rate)	Total Mean Cost	QALYs	ICER Cost/QALYs	New Event Rate** (Base Case Value)	Total Mean Cost	QALYs	ICER Cost/QALYs
OLZ	4.6% (3.3%)	$8567	0.733	Dominant	21.8% (16.8%)	$8582	0.731	Dominant
RIS	4.1% (3.2%)	$9095	0.719	-	21.4% (14.0%)	$9122	0.717	-
QUE	4.3% (3.6%)	$13628	0.708	-	21.3% (14.1%)	$13666	0.706	-
ZIP	4.1% (2.0%)	$11445	0.715	-	19.6% (8.1%)	$11478	0.711	-
ARIP	4.1% (2.0%)	$11632	0.710	-	16.7% (3.6%)	$11678	0.707	-

*Source: Leslie and Rosenheck, 2005 [84]
**Source: Olfson et al., 2006 [70]
QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio; OLZ = olanzapine; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole
Further analysis showed that olanzapine remained dominant when the rates of diabetes for aripiprazole and ziprasidone were kept at the base case value and all others were increased.

ISSN: 1478-7547